Biotech Shares Jump As Institutional Coverage Begins With Positive Outlook

By: Tomas Ronolski - AllPennyStocks.com News

Tuesday, April 29, 2025

A biotech company based out of Germany stole the show on Tuesday after it was announced that Cantor Fitzgerald initiated coverage on the stock with an Overweight rating and announced a price target of $10.

Seeing that the stock closed at just $1.22 yesterday, it’s no wonder that traders rushed to get their hands on shares of InflaRx N.V. (Nasdaq:IFRX). The buying frenzy pushed the small cap up to $1.535/share (+25.82%) at the session high, compounding this month’s success confirming the recent support this stock bounced off of earlier this month.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Copyright © 2025 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.